Cargando…
Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus
BACKGROUND AND OBJECTIVE: Obesity is globally recognized as an important clinical problem and sodium-glucose co-transporter 2 (SGLT2) inhibitors are considered a suitable therapy for obese patients with type 2 diabetes mellitus (T2DM). We examined the clinical factors associated with initial decreas...
Autores principales: | Kurinami, Noboru, Sugiyama, Seigo, Nishimura, Hiroyuki, Morita, Ayami, Yoshida, Akira, Hieshima, Kunio, Miyamoto, Fumio, Kajiwara, Keizo, Jinnouchi, Katsunori, Jinnouchi, Tomio, Jinnouchi, Hideaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762773/ https://www.ncbi.nlm.nih.gov/pubmed/29098566 http://dx.doi.org/10.1007/s40261-017-0580-6 |
Ejemplares similares
-
The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018) -
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
por: Sugiyama, Seigo, et al.
Publicado: (2018) -
Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease
por: Sugiyama, Seigo, et al.
Publicado: (2020) -
Body Muscle-to-Fat Ratio, Rather Than Fat-to-Muscle Ratio, Significantly Correlates With Measured Insulin Resistance in Patients With Type 2 Diabetes Mellitus
por: Kurinami, Noboru, et al.
Publicado: (2021) -
Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center
por: Sugiyama, Seigo, et al.
Publicado: (2019)